NEW YORK (GenomeWeb News) – Biocius Life Sciences said today that it is now an independent operating company after completing its spin out from parent company Biotrove, which was recently acquired by Life Technologies.
Biocius said that it now holds all of the intellectual property related to the RapidFire mass spectrometry platform formerly owned by Biotrove; and that it will employ all former employees of Biotrove's RapidFire business unit.
In November, Life Technologies announced that it would acquire BioTrove for an undisclosed sum to incorporate Biotrove's OpenArray high-throughput gene expression and genotyping system.
At the time, Biotrove said that it would form the Biocius subsidiary to retain the RapidFire business. Life Tech's acquisition of Biotrove was completed yesterday.
Biocius' investors include Catalyst Health Ventures, Excel Venture Management, Fletcher-Spaght, CB Health Ventures, Vox Equity Partners, Echelon Ventures, and BioFrontier Partners.
Biocius, based in Woburn, Mass., said that it will focus its resources on further developing and marketing the RapidFire platform, as well as new research and development projects to facilitate drug discovery for clients and collaborators.